The news: UK-based AstraZeneca is listing on the New York Stock Exchange—leaning into its largest market. The move follows the pharma company’s 5-year, $50 billion pledge for R&D and manufacturing in the US, even as it paused an expansion of its UK headquarters.
Why it matters: AstraZeneca’s US listing underscores how trade pressure and geopolitical risk are reshaping pharma strategies.
-
Tariff threats to the pharma industry last year accelerated US manufacturing commitments, often alongside individual company deals to lower drug prices and offer direct-to-consumer (D2C) sales.
- Drugmakers pledged more than $370 billion in US investments by 2030, per a recent DPR construction report.
- The US still produces only 11% of active pharmaceutical ingredients (API) compared with 22% made in China and 44% in India, per a recent FDA report, highlighting the gap between investment pledges and current operations.
AstraZeneca is balancing US expansion with continued global investment. It recently pledged $15 billion to China for R&D and manufacturing through 2030 and signed a drug development deal worth up to $18.5 billion with CSPC Pharmaceutical Group. However, the company expects the US to generate 50% of its projected $80 billion in sales by 2030, up from 43% of its $54 billion revenue in 2024.
Implications for pharma companies: AstraZeneca’s moves highlight how US investment is becoming a baseline expectation rather than a competitive edge. Political pressure, tariff risks, and supply chain vulnerabilities are pushing pharma companies to expand US manufacturing, but that won’t quickly unwind reliance on overseas API production.
AstraZeneca’s parallel bet in China reinforces the importance of global R&D access and speed to market. For pharma, the emerging playbook is diversification, balancing US growth, investor alignment, and regulatory pressures with dependence on global manufacturing and innovation hotspots.
This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.